StemCell Institute (JP:7096)

:7096

7096

StemCell Institute

RESEARCH TOOLSreports

Want to see JP:7096 full AI Analyst Report?

StemCell Institute (7096) Price & Analysis

0 Followers

7096 Stock Chart & Stats

¥793.00

¥110.00(8.02%)

At close: Jan 08 4:00 PM EST

¥793.00

¥110.00(8.02%)

Day’s Range― - ―

52-Week Range¥627.00 - ¥1,245.00

Previous CloseN/A

Volume70.10K

Average Volume (3M)28.64K

Market Cap

¥6.73B

Enterprise Value¥4.22B

Total Cash (Recent Filing)¥2.71B

Total Debt (Recent Filing)¥497.26M

Price to Earnings (P/E)41.9

Beta0.45

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)24.46

Shares Outstanding10,246,600

10 Day Avg. Volume23,150

30 Day Avg. Volume28,640

Financial Highlights & Ratios

PEG Ratio-0.84

Price to Book (P/B)2.88

Price to Sales (P/S)2.75

P/FCF Ratio-23.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)19.9

Revenue Forecast (FY)¥3.18B

Bulls Say, Bears Say

Bulls Say

High Gross MarginA ~61% gross margin indicates durable pricing power and attractive unit economics that help absorb cost pressures. This margin cushion supports reinvestment into R&D and commercialization and provides structural operating leverage as revenue scales, improving long-term profitability prospects.

Steady Revenue GrowthMulti-year revenue growth demonstrates persistent market demand and product adoption, reducing execution risk. A steady top line provides a platform to spread fixed costs, improve operating leverage, and fund strategic initiatives, supporting sustainable earnings improvement over the medium term.

Generally Healthy Balance SheetModest leverage and growing equity/assets provide financial flexibility to fund clinical programs or commercial expansion without immediate capital raises. A generally healthy balance sheet helps the firm absorb temporary cash shocks and pursue strategic moves such as partnerships or selective investment.

Bears Say

Deteriorating Cash GenerationA deep negative free cash flow and sharply lower operating cash flow impair self-funding ability and raise near-term refinancing or dilution risk. Sustained FCF weakness can constrain R&D and commercialization spending, increase reliance on external capital, and heighten execution risk over the next several quarters.

Sharply Weakened ProfitabilityA marked drop in net margin reduces the firm's ability to convert revenue into sustainable earnings and cash flow. Whether due to higher opex, one-offs, or pricing pressure, such compression undermines returns and makes it harder to finance growth internally, raising medium-term performance risk.

Rising Leverage With Lower ReturnsIncreasing debt while ROE falls suggests the recent capital mix change has not improved profitability and raises interest and refinancing exposure. This structural shift reduces strategic flexibility and increases vulnerability if cash flows and margins do not stabilize, elevating balance-sheet risk.

StemCell Institute News

StemCell Institute Expands into Southeast Asia with Joint Venture

The latest announcement is out from StemCell Institute ( ($JP:7096) ). StemCell Institute Inc. has entered a joint...

11M ago

7096

7096 FAQ

What was StemCell Institute’s price range in the past 12 months?

StemCell Institute lowest stock price was ¥627.00 and its highest was ¥1245.00 in the past 12 months.

What is StemCell Institute’s market cap?

StemCell Institute’s market cap is ¥6.73B.

When is StemCell Institute’s upcoming earnings report date?

StemCell Institute’s upcoming earnings report date is Aug 12, 2026 which is in 68 days.

How were StemCell Institute’s earnings last quarter?

StemCell Institute released its earnings results on May 13, 2026. The company reported ¥0.94 earnings per share for the quarter, beating the consensus estimate of N/A by ¥0.94.

Is StemCell Institute overvalued?

According to Wall Street analysts StemCell Institute’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does StemCell Institute pay dividends?

StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here

What is StemCell Institute’s EPS estimate?

StemCell Institute’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does StemCell Institute have?

StemCell Institute has 10,246,600 shares outstanding.

What happened to StemCell Institute’s price movement after its last earnings report?

StemCell Institute reported an EPS of ¥0.94 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.37%.

Which hedge fund is a major shareholder of StemCell Institute?

Currently, no hedge funds are holding shares in JP:7096

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

StemCell Institute

StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.